Myelodysplastic/Myeloproliferative Neoplasms
92
4
4
60
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
19 trials with published results (21%)
Research Maturity
60 completed trials (65% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
18.5%
17 terminated out of 92 trials
77.9%
-8.6% vs benchmark
13%
12 trials in Phase 3/4
32%
19 of 60 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 60 completed trials
Clinical Trials (92)
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study
Registry of Older Patients With Cancer
Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia
Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma
Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults
Collecting and Storing Blood Samples From Patients With Cancer
Bone Marrow Transplant in Treating Patients With Hematologic Cancers
Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Interleukin-2 in Treating Patients With Myelodysplastic Syndrome
Cholecalciferol in Treating Patients With Myelodysplastic Syndrome
Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia